Spyridon Komaitis

Dr. Spyridon Komaitis

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CKChristos Koutsarnakis
Christos Koutsarnakis
ENEleftherios Neromyliotis
Eleftherios Neromyliotis
Spyridon KomaitisSpyridon Komaitis
Spyridon Komaitis
NMNektarios Mazarakis
Nektarios Mazarakis
DODaniel J. O'Hara
Daniel J. O'Hara
PCPaul Chumas
Paul Chumas

27 January 2025 in Brain
Verified
Journal Article
Open access
GSGeorgios P Skandalakis
Georgios P Skandalakis
LVLuca Viganò
Luca Viganò
CNClemens Neudorfer
Clemens Neudorfer
Marco RossiMarco Rossi
Marco Rossi
LFLuca Fornia
Luca Fornia
LELinton T Evans
Linton T Evans
The somato-cognitive action network (SCAN) consists of three nodes interspersed within Penfield’s motor effector regions. The configuration of the somato-cognitive action network nodes resembles the one of the ‘plis de passage’ of the central sulcus: small gyri bridging the precentral and postcentral gyri. Thus, we hypothesize that these may provide a structural substrate of the somato-cognitive action network. Using microdissections of 16 human hemispheres, we consistently identified a chain of three distinct plis de passage with increased underlying white matter in locations analogous to the somato-cognitive action network nodes. We mapped localizations of plis de passage into standard stereotactic space to seed functional MRI connectivity across 9000 resting-state functional MRI scans, which demonstrated the connectivity of these sites with the somato-cognitive action network. Intraoperative recordings during direct electrical central sulcus stimulation further identified inter-effector regions corresponding to plis de passage locations. This work provides a critical step towards an improved understanding of the somato-cognitive action network in both structural and functional terms. Furthermore, our work has the potential to guide the development of refined motor cortex stimulation techniques for treating brain disorders and operative resective techniques for complex surgery of the motor cortex.

29 May 2024 in Brain
Verified
Journal Article
Open access
PDF file
GSGeorgios P Skandalakis
Georgios P Skandalakis
CNClemens Neudorfer
Clemens Neudorfer
CPCaitlin A Payne
Caitlin A Payne
EBEvalina Bond
Evalina Bond
ATArmin D Tavakkoli
Armin D Tavakkoli
AKAristotelis Kalyvas
Aristotelis Kalyvas
Comprehensive understanding of the neural circuits involving the ventral tegmental area is essential for elucidating the anatomofunctional mechanisms governing human behaviour, in addition to the therapeutic and adverse effects of deep brain stimulation for neuropsychiatric diseases. Although the ventral tegmental area has been targeted successfully with deep brain stimulation for different neuropsychiatric diseases, the axonal connectivity of the region is not fully understood. Here, using fibre microdissections in human cadaveric hemispheres, population-based high-definition fibre tractography and previously reported deep brain stimulation hotspots, we find that the ventral tegmental area participates in an intricate network involving the serotonergic pontine nuclei, basal ganglia, limbic system, basal forebrain and prefrontal cortex, which is implicated in the treatment of obsessive–compulsive disorder, major depressive disorder, Alzheimer’s disease, cluster headaches and aggressive behaviours.

19 December 2016 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
GKGeorge Karagkounis
George Karagkounis
GSGeorge Stranjalis
George Stranjalis
TATheodore Argyrakos
Theodore Argyrakos
VPVarvara Pantelaion
Varvara Pantelaion
KMKonstantinos Mastoris
Konstantinos Mastoris
DTDina Tiniakos
Dina Tiniakos
Aims: To study anaplastic lymphoma kinase (ALK) protein expression and possible underlying gene alterations in glioblastoma (GBM), correlating them with clinical outcome. Methods: We studied ALK immunohistochemical expression and fluorescent in situ hybridisation (FISH)-detected ALK gene alterations in 51 GBMs (46 isocitrate dehydrogenase-1 (IDH1) R132H -negative and 5 IDH-mutant (IDH1 R132H -positive)). We compared two anti-ALK antibodies and immunohistochemical detection systems (5Α4/Nichirei Biosciences, D5F3/Ventana). The results were correlated with tumour cell proliferation and clinical outcome. Results: Intense granular cytoplasmic ALK immunostaining was observed in 10/51 (19.61%) GBM and correlated with high Ki67 proliferation index; only 1 in 10 ALK-positive cases displayed multiple alk gene signals by FISH. Moderate ALK immunostaining was observed in 21 (41.17%), weak immunostaining in 5 (9.80%) while 15 (29.42%) cases were negative. p53 was expressed in 26/51 GBM (50.9%) (10% cut-off). IDH1 R132H -negative GBM showed higher ALK expression compared with IDH-mutant GBM (65.2% vs 20%). ALK overexpression was more common in older patients but did not correlate with other clinicopathological variables or patient overall survival. Conclusions: ALK overexpression can be identified in up to 70% of GBMs and does not correlate with underlying alk gene amplification. Despite being more common in rapidly growing, clinically aggressive GBM, ALK overexpression did not show correlation with prognosis in this study.

22 November 2019 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
CKChristos Koutsarnakis
Christos Koutsarnakis
Spyridon KomaitisSpyridon Komaitis
Spyridon Komaitis
EDEvangelos Drosos
Evangelos Drosos
AKAristotelis V. Kalyvas
Aristotelis V. Kalyvas
GSGeorgios P. Skandalakis
Georgios P. Skandalakis
GSGeorge Stranjalis
George Stranjalis

7 January 2023 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
ENElie Najjar
Elie Najjar
MHMohamed A. Hassanin
Mohamed A. Hassanin
Spyridon KomaitisSpyridon Komaitis
Spyridon Komaitis
FKFaris Karouni
Faris Karouni
NQNashir A. Quraishi
Nashir A. Quraishi